proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.

The BreathID technology platform answers the long-standing need for fast, convenient and accurate assessment and monitoring of functional diseases of the liver and gastrointestinal tract. It measures parts-per-million changes in the molecular 13C/12C ratio of the patient's exhaled breath - continuously, automatically and in real time. BreathID products are designed for mobility and user-friendly operation, and can be performed in the office or clinic.

The company’s flagship Breath ID Hp is an extremely accurate, easy-to-use, self-calibrating urea breath test (UBT) and the emerging gold standard to diagnose, monitor and manage gastric H. pylori bacteria infection. It is estimated that two-thirds of the world's population is infected with H. pylori. Recent studies estimate that more than 90% of duodenal ulcers and 80% of gastric complications are caused by H. pylori, conditions which have been to ultimately lead to stomach cancer and other gastric complications if left untreated.

The design of sophisticated diagnostic systems that are simple to operate is a hallmark of Exalenz. The company conducts ongoing research in collaboration with leading clinical and industrial partners in the U.S., Europe, Asia, and Israel.

Exalenz’ mission is to become a leading provider of accurate, breath test-based, point-of-care disease management solutions for a broad range of GI and liver disorders.

As their name implies, they define "excellence" as successfully meeting patient and practitioner needs. Their technology furthers this goal by providing both medical professionals and patients with advanced solutions and vital diagnostic information.